OCULAR THERAPEUTIX INC. - COMMON STOCK

Ocular Therapeutix™ Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO

15 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Senior Vice President of Global Head of Biometrics

09 Apr 2024 07:30:00 By Nasdaq GlobeNewswire

Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting

06 Apr 2024 10:00:00 By Nasdaq GlobeNewswire

Ocular Therapeutix™ To Present Data at the 2024 ASCRS Annual Meeting (American Society of Cataract and Refractive Surgery)

26 Mar 2024 07:30:00 By Nasdaq GlobeNewswire

Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2023 Results

11 Mar 2024 16:05:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: OCULAR THERAPEUTIX INC. - COMMON STOCK

06 Mar 2024 10:53:23 By NetDania Notify

Ocular Therapeutix™ to Release Fourth Quarter and Full Year 2023 Results on March 11, 2024

05 Mar 2024 07:30:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: OCULAR THERAPEUTIX INC. - COMMON STOCK

04 Mar 2024 09:45:09 By NetDania Notify

NetDania - New 12 months High: OCULAR THERAPEUTIX INC. - COMMON STOCK

01 Mar 2024 12:02:47 By NetDania Notify

NetDania - New 12 months High: OCULAR THERAPEUTIX INC. - COMMON STOCK

26 Feb 2024 09:47:12 By NetDania Notify

NetDania - New 12 months High: OCULAR THERAPEUTIX INC. - COMMON STOCK

23 Feb 2024 10:33:55 By NetDania Notify

NetDania - New 12 months High: OCULAR THERAPEUTIX INC. - COMMON STOCK

22 Feb 2024 09:45:24 By NetDania Notify

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Executive Chairman and Chief Strategy Officer

22 Feb 2024 07:32:00 By Nasdaq GlobeNewswire

Ocular Therapeutix, Inc. Announces $325.0 Million Private Placement

22 Feb 2024 07:31:00 By Nasdaq GlobeNewswire

Ocular Therapeutix™ Announces Board of Directors and Leadership Updates

22 Feb 2024 07:30:00 By Nasdaq GlobeNewswire

Ocular Therapeutix™ Appoints Steve Meyers to Chief Commercial Officer

15 Feb 2024 08:00:00 By Nasdaq GlobeNewswire

Ocular Therapeutix™ Announces First Subjects Screened in Phase 3 Pivotal Clinical Trial of AXPAXLI™ in Wet AMD

13 Feb 2024 07:38:24 By Nasdaq GlobeNewswire

Ocular Therapeutix™ Announces FDA Agreement to Amend Special Protocol Assessment (SPA) for Pivotal Clinical Trial of AXPAXLI™ in Wet AMD

25 Jan 2024 08:00:00 By Nasdaq GlobeNewswire

Ocular Therapeutix™ Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

18 Dec 2023 16:01:00 By Nasdaq GlobeNewswire

Ocular Therapeutix™ Announces Pricing of Public Offering of Common Stock

13 Dec 2023 22:09:58 By Nasdaq GlobeNewswire